Fudan University

Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in China

Retrieved on: 
Tuesday, August 9, 2022 - 10:00am
FDA, Proteolysis targeting chimera, CEO, CDE, Kintore, Northern Territory, Breast, Technology, Patient, COVID-19, PROTAC, Prostate, Hair loss, Data analysis, HKEX, Pi, Acne, Fudan University, Safety, AGA, US Foods, Huashan Hospital, AR, Pharmacokinetics, Hair, Pharmaceutical industry, Chimera

The leading principal investigators (leading PIs) of the phase I clinical trial are Professor Zhang Jing and AssociateProfessor Wu Xiaojie from Huashan Hospital affiliated to Fudan University.

Key Points: 
  • The leading principal investigators (leading PIs) of the phase I clinical trial are Professor Zhang Jing and AssociateProfessor Wu Xiaojie from Huashan Hospital affiliated to Fudan University.
  • Dr. Youzhi Tong, founder, Chairman, and CEO of Kintor Pharma, commented, "Both indications of AGA and acne have great unmet clinical needs.
  • As the world's first company to develop a topical AR-PROTAC compound, Kintor is currently conducting phase I clinical trials of GT20029 in China and the United States.
  • In July 2021, Kintor announced the dosing of first batch of subjects in its China phase I clinical trial of GT20029.In February 2022,Kintor announced the dosing of first subjectin its USphase I clinical trial of GT20029.

Zhaoke Ophthalmology Completed Patient Enrollments for the Phase III Clinical Trials of the Myopia Progression Treatment Drug NVK002

Retrieved on: 
Wednesday, August 3, 2022 - 2:16am
World, Motherboard, Atropine, Ageing, State Council, Parent, Eye, Safety, Episode I, Sun, Ministry, Director, Company, Fudan University, S. D. Warren Co. v. Maine Board of Environmental Protection, Eye and ENT Hospital of Fudan University, Control, Research, World Health Organization, Technology, US Foods, Growth, List of education ministries, Education, Business, Adolescence, Food, SEHK, CEO, Board, Ophthalmology, Achievement, FDA, Benjamin, National Health Planning and Resources Development Act, Cover My Eyes (Pain and Heaven), Approximation error, Beijing Tongren Hospital, NDA, CIC, The Company, Hospital, Principal, Hong Kong Stock Exchange, Patient, Overalls, Pharmaceutical industry, Vaccine, Medical imaging, Myopia

The primary objective of the China CHAMP and Mini-CHAMP trials is to evaluate the efficacy and safety of NVK002 for the treatment of myopia progression in children and adolescents.

Key Points: 
  • The primary objective of the China CHAMP and Mini-CHAMP trials is to evaluate the efficacy and safety of NVK002 for the treatment of myopia progression in children and adolescents.
  • These early completions of patient recruitment across both trials, gives the company a strong headstart in moving towards its goal to lead the market in launching a myopia progression treatment drug.
  • Following this, a New Drug Application ("NDA") submission to the US Food and Drug Administration (the "FDA") is expected in 2023.
  • Dr. Li Xiaoyi (Benjamin), Chairman of the Board of Directors, Executive Director and CEO of Zhaoke Ophthalmology, said, "The early completion of the patient recruitment of NVK002's Phase III clinical trials marks another huge and exciting milestone for Zhaoke Ophthalmology.

CARsgen Appoints Dr. Hua Jiang as Executive Director

Retrieved on: 
Tuesday, August 2, 2022 - 1:50pm
Jining Medical University, SCI, View, Trust, Development, CAR, Research, Executive, Shanghai Jiao Tong University School of Medicine, National Cancer Institute, Board, Journal of the National Cancer Institute, Multimedia, Shandong University, Pharmacology, Cancer, Medicine, Clinical Cancer Research, Journal, Executive director, Company, Patient, Fudan University, Molecular Therapy, Oregon Economic and Community Development Department, Pharmaceutical industry, Management

SHANGHAI, Aug. 2, 2022 /PRNewswire/ --CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that Dr. Hua Jiang ("Dr. Jiang") has been appointed as Executive Director of the Company.

Key Points: 
  • SHANGHAI, Aug. 2, 2022 /PRNewswire/ --CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that Dr. Hua Jiang ("Dr. Jiang") has been appointed as Executive Director of the Company.
  • Dr. Jiang has contributed significantly to the early research, technology platform development, and innovative products development in CARsgen.
  • Dr. Zonghai Li, Founder, Chairman of the Board, Chief Executive Officer, and Chief Scientific Officer of CARsgen, added, "On behalf of the Board, I would like to congratulate Dr. Jiang to be appointed as the Executive Director.
  • Dr. Hua Jiang, Executive Director, Vice President of Early Discovery of CARsgen, said, "I am pleased to become a member of the Board and would like to thank the Board for the recognition and trust.

Redesigning the Future of Aesthetic Medicine: Bellesoma® Welcomes Industry Leader, Vincent Wu, as New Chief Commercial Officer

Retrieved on: 
Monday, August 1, 2022 - 1:32pm
AI, Surgeon, Skin, Human, Business, Surgical mesh, Woman, CEO, Social media, Breast, Kelley School of Business, Technology, MBA, Reduction, Patient, Heart, Foreign Bodies, NP-hardness, Neck, IOT, Fudan University, Medical device, Management, Birth control, Mastopexy, Biotechnology

Wu is an industry disruptor, having already applied his marketing philosophies to multiple global businesses delivering results at a multibillion-dollar level.

Key Points: 
  • Wu is an industry disruptor, having already applied his marketing philosophies to multiple global businesses delivering results at a multibillion-dollar level.
  • "We're excited and lucky to have Vincent join our team," said Adam Cohen, CEO of Bellesoma.
  • "Startups are always a challenging business, and even the best of them can falter without a strong vision and a fantastic team.
  • Before joining Bellesoma, Vincent also helped create the first IOT home dialysis solution, along with new business models of hospital consultancy.

Apollomics Inc. Expands Leadership Team with Appointment of Jane Wang, PhD as Chief Scientific Officer

Retrieved on: 
Tuesday, July 26, 2022 - 12:10pm
Chemistry, University, Wuxi, GLOBE, Pfizer, Schering-Plough, Doctor of Philosophy, History of the University of Maryland, College Park, Research, Drug discovery, Medicinal chemistry, Patent, Inflammation, Central nervous system, University of Maryland, Baltimore County Centers and Institutes, Publication, Company, Fudan University, Entrepreneurship, RNA, Pharmaceutical industry

FOSTER CITY, Calif. and HANGZHOU, China, July 26, 2022 (GLOBE NEWSWIRE) -- Apollomics Inc. an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced the appointment of Jane Wang, PhD as Chief Scientific Officer.

Key Points: 
  • FOSTER CITY, Calif. and HANGZHOU, China, July 26, 2022 (GLOBE NEWSWIRE) -- Apollomics Inc. an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced the appointment of Jane Wang, PhD as Chief Scientific Officer.
  • She will also serve as Apollomics China General Manager and will report to the Chief Executive Officer.
  • We are very excited to have Jane join our team, said Guo-Liang Yu, PhD, Co-Founder, Chairman and Chief Executive Officer.
  • I look forward to growing our global team to discover and advance new compounds into the clinic, added Jane Wang, PhD, Chief Scientific Officer.

Apollomics Inc. Expands Leadership Team with Appointment of Jane Wang, PhD as Chief Scientific Officer

Retrieved on: 
Tuesday, July 26, 2022 - 1:17am
CA, Chemistry, University, Wuxi, Pfizer, Schering-Plough, Doctor of Philosophy, History of the University of Maryland, College Park, Research, National Institute, Drug discovery, Medicinal chemistry, Patent, Immune system, Inflammation, Central nervous system, University of Maryland, Baltimore County Centers and Institutes, Publication, Company, Fudan University, Entrepreneurship, RNA, Pharmaceutical industry

Foster City, CA, and Hangzhou, China, July 26, 2022 - (ACN Newswire) - Apollomics Inc. an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced the appointment of Jane Wang, PhD as Chief Scientific Officer.

Key Points: 
  • Foster City, CA, and Hangzhou, China, July 26, 2022 - (ACN Newswire) - Apollomics Inc. an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced the appointment of Jane Wang, PhD as Chief Scientific Officer.
  • She will also serve as Apollomics' China General Manager and will report to the Chief Executive Officer.
  • "We are very excited to have Jane join our team," said Guo-Liang Yu, PhD, Co-Founder, Chairman and Chief Executive Officer.
  • I look forward to growing our global team to discover and advance new compounds into the clinic," added Jane Wang, Ph.D., Chief Scientific Officer.

Rerun the Legend of New York, EIC Reinitiating Epoch-making Urban Upgrading

Retrieved on: 
Tuesday, July 19, 2022 - 8:03am
Sustainability, Environment, Finance, Banking, Environmental Issues, Professional Services, Fintech, Green Technology, Carbon, European Innovation Council, London and Partners, Leadership in Energy and Environmental Design, Partner, G5, Economics, Gold, Institute of Botany, Chinese Academy of Sciences, Host, City, LEED, Fudan University, London, Schools of economic thought, School, EIC, WELL, General manager, IFC, IFS, Development, Forum, Multimedia, Yangtze Delta, Economic development, NIO, Nature, Northeast Project of the Chinese Academy of Social Sciences, ESG, Senior Executive Service Accountability Act, Jinan Center Financial City, Social science, Exhibition, Renewable energy

View the full release here: https://www.businesswire.com/news/home/20220719005572/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220719005572/en/
    EIC Reinitiating Epoch-making Urban Upgrading (Photo: Business Wire)
    The Forum presented a panorama of green finance and sustainable development for all.
  • This is due to the fact that EIC, the Host of this Summit Forum, is also a firm practitioner of the path of green development.
  • At the same time, EIC has received both the WELL Gold Precertification and the LEED Gold Precertification.
  • At this Forum, the Senior Executives of WELL and LEED also spoke highly of EIC.

Silk Road Online Curating Competition Attracts Participation of over 120 Universities

Retrieved on: 
Monday, July 11, 2022 - 3:45am
Online, Exhibition, University of Florida Digital Collections, Zhejiang University, Peking University, Chinese Museum (Fontainebleau), University, KOOL, China National Silk Museum, SROM, Digital curation, Breast, University of the Arts London, Multimedia, Catalog of paintings in the Louvre Museum, Artifact, Silk Road, Fudan University, Shanghai University, Urban Design Group, Silk, Museum, Silkroad Online, Social media, Entertainment, 3D printing

HANGZHOU, China, July 10, 2022 /PRNewswire/ -- The China National Silk Museum held the Silk Road Online Curating Competition from April to July 2022, co-organized by Shanghai University and supported by Manycore Tech Inc. (KOOL).

Key Points: 
  • HANGZHOU, China, July 10, 2022 /PRNewswire/ -- The China National Silk Museum held the Silk Road Online Curating Competition from April to July 2022, co-organized by Shanghai University and supported by Manycore Tech Inc. (KOOL).
  • The competition attracted the participation of over 120 universities including Peking University, Fudan University, Zhejiang University, University of the Arts London and many other universities, as well as more than 20 museums and a large group of designers.
  • The competition is powered by the Silk Road Online Museum (SROM) platform, a platform with its main concepts focusing on "digital collaboration" and "3D online curating".
  • The Silk Road Online Curating Competition culminated on the evening of July 8, with an award ceremony held in the China National Silk Museum.

Burning Rock Announces the Launch of China’s First Prospective Interventional Validation Study on Multi-Cancer Early Detection - the PREVENT Study

Retrieved on: 
Thursday, June 30, 2022 - 3:57pm
Diagnosis, U.S. News & World Report Best Hospitals Rankings, Science, Patient, CEO, Sichuan University, Liver, Securities Exchange Act of 1934, Research, NGS, Second Affiliated Hospital of Xinjiang Medical University, GLOBE, Cancer, Annual report, Forward-looking statement, Terminology, Hope, Compliance, Fudan University, Policy, Wuhan Union Hospital, Hospital, Technology, Intervention, Lung, Quality of life, SEC, ISBN, Incidence, Medical school, Private Securities Litigation Reform Act, NASDAQ, Pathology, Dalian Medical University, Physician, WCH, Medical imaging, Water Drops on Burning Rocks

The study is led by Dr. Weimin Li, head of the West China Hospital of Sichuan University.

Key Points: 
  • The study is led by Dr. Weimin Li, head of the West China Hospital of Sichuan University.
  • "Cancer early detection, diagnosis and treatment is the key to reducing cancer burden.
  • "The PREVENT study is at the cutting edge of cancer early detection and management.
  • Yusheng Han, CEO of Burning Rock, remarked that "Multi-cancer early detection through liquid-biopsy is a strategic focus of Burning Rock.

China Daily series Youth Power：Gen Zers discuss "One country, two systems, three cheers"

Retrieved on: 
Thursday, June 30, 2022 - 2:25pm
Memory, Hatred, Travel, Love, Identity, Wuhan University, Element, Dream, Tsinghua University, Multimedia, Political science, History, Hostility, Fudan University, Chinese University of Hong Kong, Culture, Chinese, Child, Guangdong-Hong Kong-Macau Greater Bay Area, Youth Power, Program, China University of Political Science and Law, Education, Tutoring, Toy, Casino, Road

TheGen Zers who took part discussed childhood memories and identity and cultural differences relating to Hong Kong and the mainland.

Key Points: 
  • TheGen Zers who took part discussed childhood memories and identity and cultural differences relating to Hong Kong and the mainland.
  • For example, Cantonese songs, TV programs, Hong Kong stars and celebrities and other elements of Hong Kong pop culture are a common memory and love of Gen Zers.
  • Gen Zers in Hong Kong and Macao also enjoy variety shows from the mainland.
  • Those in the program said they hoped people from both Hong Kong and the mainland would cherish their shared history and culture.